Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.61 |
| ▸ | CES1 | P23141 | 2/20 | 0.61 |
| ▸ | MPO | P05164 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | KDM5A | P29375 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | GFER | P55789 | 1/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | OGG1 | O15527 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14476625 | 0.94 | KIF11 (0.56) | CES2CES1MPOCYP3A4KDM5A | |
| SCHEMBL30378627 | 0.86 | CES2 (0.55) | CES2CES1PTGS1PTPN1GSK3B | |
| SCHEMBL2678949 | 0.83 | MPO (0.80) | MPOCYP3A4KDM5ABLMGFER | |
| SCHEMBL343630 | 0.83 | MPO (0.80) | MPOCYP3A4KDM5ABLMGFER | |
| SCHEMBL8928282 | 0.83 | MPO (0.55) | CES2CES1MPOCYP3A4KDM5A | |
| SCHEMBL21434671 | 0.83 | MPO (0.55) | MPOCYP3A4KDM5ABLMGFER | |
| SCHEMBL28188923 | 0.81 | MPO (0.76) | MPOCYP3A4KDM5ABLMGFER | |
| SCHEMBL3277286 | 0.81 | GAA (0.61) | CES2BLMALDH1A1KDM4EMAPT | |
| SCHEMBL29987081 | 0.80 | PTPN1 (0.75) | CES2CES1ALDH1A1MAPTPTPN1 | |
| SCHEMBL14880225 | 0.80 | CES2 (0.64) | CES2CES1PTGS1SRD5A2TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 390 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116253674-A | Method for preparing tecovirime | 青岛增益安生物科技有限公司 | 2023-06-13 | — | — | CN | claimed |
| US-11398630-B2 | Method of generating energy from a hydrazide containing anode fuel, and fuel cell | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2022-07-26 | — | — | US | claimed |
| CN-110117235-B | Compound with aggregation-induced light emission and mechanochromism characteristics and preparation method and application thereof | 江苏萨瑞斯医疗科技有限公司 | 2022-05-31 | — | — | CN | claimed |
| CN-112645940-A | 1,3, 4-oxadiazole-norfloxacin heterozygote and preparation method and application thereof | 广东省微生物研究所（广东省微生物分析检测中心） | 2021-04-13 | — | — | CN | claimed |
| CN-112592339-A | 1,3, 4-oxadiazole-2 (3H) -thione-norfloxacin heterozygote and preparation method and application thereof | 广东省微生物研究所（广东省微生物分析检测中心） | 2021-04-02 | — | — | CN | claimed |
| US-20210005900-A1 | METHOD OF GENERATING ENERGY FROM A HYDRAZIDE CONTAINING ANODE FUEL, AND FUEL CELL | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2021-01-07 | — | — | US | claimed |
| CN-110117235-A | The compound and its preparation method and application of color shifting properties is caused with aggregation-induced emission and power | 江苏萨瑞斯医疗科技有限公司 | 2019-08-13 | — | — | CN | claimed |
| EP-1638938-B1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES | SIGA TECH INC (US) | 2017-04-12 | — | — | EP | claimed |
| CN-104710379-B | Synthetic method for BMS-191011 | 华南理工大学 | 2017-01-18 | — | — | CN | claimed |
| CN-104758281-A | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES INC | 2015-07-08 | — | — | CN | claimed |
| EP-1392219-A2 | SUBSTITUTED N'-(ARYLCARBONYL)-BENZHYDRAZIDES, N'-(ARYLCARBONYL)-BENZYLIDENE-HYDRAZIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2004-03-03 | — | — | EP | claimed |
| US-20030105140-A1 | Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-06-05 | — | — | US | claimed |
| US-20030013743-A1 | Substituted N'-(arylcarbonyl)-benzhydrazides, N'-(arylcarbonyl)-benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-01-16 | — | — | US | claimed |
| WO-2002102301-A2 | SUBSTITUTED INDOLE-2-CARBOXYLIC ACID BENZYLIDENE-HYDRAZIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2002-12-27 | — | — | WO | claimed |
| WO-2002089745-A2 | SUBSTITUTED N'-(ARYLCARBONYL)-BENZHYDRAZIDES, N'-(ARYLCARBONYL)-BENZYLIDENE-HYDRAZIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2002-11-14 | — | — | WO | claimed |
| EP-1252146-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2002-10-30 | — | — | EP | claimed |
| US-20020128292-A1 | Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2002-09-12 | — | — | US | claimed |
| WO-2001053274-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2001-07-26 | — | — | WO | claimed |
| US-4649148-A | Insecticidal uses of diaminoguanidine hydrazone compounds | AMERICAN CYANAMID COMPANY (US) | 1987-03-10 | — | — | US | claimed |
| US-4575560-A | ANTIFEEDING AGENTS | AMERICAN CYANAMID COMPANY (US) | 1986-03-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128292-A1 | Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | BAD, API5, CASP2 | CES2 3460/4885CES1 2554/4885MPO 2665/4885 |
| US-20030105140-A1 | Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | BAD, API5, CASP2 | CES2 3460/4885CES1 2554/4885MPO 2665/4885 |
| US-20030013743-A1 | Substituted N'-(arylcarbonyl)-benzhydrazides, N'-(arylcarbonyl)-benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP2, CASP1, BCL2 | CES2 3084/4885CES1 2416/4885MPO 1942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.